New UK Cancer Drug Fund Marks Shift in Market Access Landscape
The Recent unveiling of the new Cancer Drugs Fund (CDF) in the UK highlights a major shift within the market access landscape, although it has caused trepidation amongst pharma and patient groups, in addition to raising some difficult questions about HTA processes. The newly proposed CDF structure was delayed, partly due to the political vacuum